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ABSTRACT: Erysipelothrix rhusiopathiae is the causative agent of erysipeloid in humans and of 22 
erysipelas in various animals, including bottlenose dolphins (Tursiops truncatus) in which an 23 
infection has the potential to cause peracute septicemia and death. The purpose of this study was 24 
to evaluate the efficacy of using an off label porcine (ER BAC PLUS®, Zoetis Inc.) 25 
Erysipelothrix rhusiopathiae bactrin in a bottlenose dolphin vaccination program by determining 26 
the anti-E. rhusiopathiae antibody levels in vaccinated dolphins over a 10 year period. Serum 27 
samples (n = 88) were analyzed using a modified fluorescent microbead immunoassay from 54 28 
dolphins, including three with no history of vaccination, 51 dolphins with an average of five 29 
vaccinations, three of which had previously recovered from a natural E.rhusiopathiae infection. 30 
A mean 311-fold increase in IgG antibody index was measured in a subsample of ten dolphins 14 31 
d after the first booster vaccination. Serum IgG antibodies titers were influenced by number of 32 
vaccines received (r2 = 0.47, p < 0.05), but not by age, gender, history of natural infection, 33 
adverse vaccine reaction, vaccination interval or time since last vaccination. The commercial pig 34 
bacterin was deemed effective in generating humoral immunity against E.rhusiopathiae in 35 
dolphins. However, since the probability of an adverse reaction toward the vaccine was 36 
moderately correlated (p = 0.07, r2 = 0.1) with number of vaccines administered, more research 37 
is needed to determine the optimal vaccination interval. 38 
 39 
KEY WORDS: Dolphin, Tursiops truncatus, Erysipelas, Erysipelothrix rhusiopathiae, Vaccine, 40 
Prophylaxis 41 
 42 
 43 
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INTRODUCTION 45 
 46 
The bacterial genus Erysipelothrix consists of three species, the type species E. rhusiopathiae, E. 47 
tonsillarum and E. inopinata (Walker 2004).  Erysipelothrix rhusiopathiae can be isolated from 48 
the environment and from a variety of animal tissues. Infections with E. rhusiopathiae are 49 
common in pigs and turkeys and have also been reported in sheep, emus, chickens, penguins and 50 
other species (Swan & Lindsey 1998, Boerner et al. 2004, Walker 2004, Eamens et al. 2006, 51 
Kurian et al. 2012). The clinical manifestation of E. rhusiopathiae infection is commonly 52 
referred to as erysipelas in domestic animals and as erysipeloid in humans. In pigs, there are 53 
three main clinical forms (Brooke & Riley 1999, Walker 2004). The acute septicemic form is 54 
usually fatal when left untreated. Clinical signs can include any combination of sudden death, 55 
fever, lethargy, depression, stiff gait, reluctance to move, inappetence and characteristic pink, red 56 
or purple raised firm rhomboid skin lesions sometimes also called “diamond skin lesions”. This 57 
second subacute form is also associated with bacteremia but is clinically less severe than the 58 
acute form with lower mortality rates and quicker recovery of affected pigs. The third chronic 59 
form in pigs is often a consequence of acute, subacute or even subclinical E. rhusiopathiae 60 
infection with localized lesions in the heart (endocarditis) or joints (arthritis) (Brooke & Riley 61 
1999, Walker 2004). 62 
Disease caused by Erysipelothrix has been recognized and confirmed in several species of 63 
dolphins and whales, both in human care and in the wild (Young et al. 1997, Dunn et al. 2001, 64 
Melero et al. 2016). Two presentations of erysipelas have been reported in dolphins. A cutaneous 65 
form, characterized by raised rhomboidal or diamond shaped skin lesions, and a septicemic form 66 
(Dunn et al. 2001). While the septicemic form can be treated successfully by the prompt 67 
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administration of appropriate antibiotics, this condition often leads to death, since it is usually 68 
only preceded by very brief (hours) non-specific clinical signs such as decreased activity levels 69 
and appetite.  The bacteremia is consequently often only recognized on necropsy (Dunn et al. 70 
2001). Erysipelothrix rhusiopathiae causes no known disease in fish but can survive for long 71 
periods of time on the mucoid exterior slime coat of fish (Wood 1975). Human erysipeloid is 72 
frequently contracted following infection of superficial injuries sustained during swimming, 73 
fishing or handling seafood (Finkelstein & Oren 2011).  The exact port of entry of the bacteria is 74 
unknown, but dolphins, like humans are presumed to contract E. rhusiopathiae from the slime 75 
coat of their food fish. Superficial cutaneous injuries could make this exposure route more likely.   76 
In swine and poultry, the prevention of erysipelas has largely relied on vaccination using 77 
attenuated live or inactivated bacteria or more recently recombinant antigens (Swan & Lindsey 78 
1998, Eamens et al. 2006, Kurian et al. 2012). In these species, challenge studies have shown 79 
that vaccination conveys effective protection against all clinical manifestations, including death 80 
(Swan & Lindsey 1998, Imada et al. 2003, Eamens et al. 2006).  Because of the bacteria’s 81 
potential to cause death without obvious premonitory signs in dolphins, prevention of 82 
Erysipelothrix rhusiopathiae infection by vaccination has been of interest to marine mammal 83 
health professionals (Nollens et al. 2005, Walsh et al. 2005).  Since no bottlenose dolphin-84 
specific vaccine is available, the use of commercial swine erysipelas vaccines has been explored 85 
(Lacave et al. 2001, Nollens et al. 2005).  Initial vaccination programs in cetaceans with 86 
commercial bacterins were abandoned because of adverse reactions consisting of both site 87 
reactions and anaphylaxis associated with the immunizations (Dunn et al. 2001).  More recently, 88 
a commercial inactivated swine Erysipelothrix vaccine (Eurovac Ery, Eurovet) developed in 89 
Europe was found to provide safe and effective crossprotection in a mice experimentally infected 90 
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with E. rhusiopathiae isolates from dolphins (Lacave et al. 2001), however, the production of 91 
this vaccine has since been discontinued.  Efforts to develop a DNA-based vaccine encoding the 92 
immunogenic 65 kDa E. rhusiopathiae surface protein proved ineffective and have been 93 
abandoned (Dunn et al., 2001).  Earlier work has demonstrated that the recombinant p64 surface 94 
protein of E. rhusiopathiae that is employed in a commercial erysipelas vaccine for swine (ER 95 
BAC PLUS®, Zoetis Inc) is immunogenic to bottlenose dolphins (Nollens et al. 2007, Bernal-96 
Guadarrama et al. 2014). Since 2003, bottlenose dolphins housed at the various SeaWorld parks 97 
have received this vaccine as part of the routine preventative medicine program (Walsh et al. 98 
2005). The purpose of this study was to evaluate the effectiveness of the vaccination program by 99 
quantifying the IgG antibody levels developed in response to vaccination, and exploring 100 
biological factors influencing antibody levels in dolphins post vaccination. 101 
MATERIALS AND METHODS 102 
Animals 103 
Fifty-four bottlenose dolphins (Tursiops truncatus) (22 male and 32 female) were group housed 104 
in habitats at either SeaWorld Florida or SeaWorld California.  Animals were fed a diet of 105 
frozen-thawed whole fish, which contained some or all of the following fish species: Pacific 106 
herring (Clupea harengus), Columbia river smelt (Thaleichthys pacificus), Pacific sardines 107 
(Sardinops sagax), Atka mackerel (Pleurogrammus azonus), and squid (Loligo sp.) at 108 
approximately 3% of their body weight per day.  All food fish was graded for human 109 
consumption. Animals were supplemented with Vita-Zu Marine Mammal tablets (Mazuri)  which 110 
contain vitamins and folic acid. 111 
Immunizations 112 
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A total of 298 immunizations were delivered to 51 bottlenose dolphins (2 to 11 for each dolphin) 113 
between 10 March 2003 and 19 February 2013 following the manufacturer’s directions for pigs.  114 
Each dolphin received 2 ml of a commercial Erysipelothrix rhusiopathiae bacterin (ER BAC 115 
PLUS®) in the dorsal musculature lateral and cranial of the dorsal fin.  All 51 dolphins received 116 
a primer vaccination, followed by a first booster vaccination 29 (± 18) days after the initial 117 
immunization, followed by either semi-annual (n = 10 dolphins) or annual (n = 41 dolphins) 118 
booster vaccinations.  After each immunization, all animals were monitored for adverse reactions 119 
(listlessness, nausea or vomiting) for 60 min.  Three dolphins were never immunized and were 120 
included as negative controls. 121 
Sample collection, processing and storage 122 
Fasting blood samples (n = 88) were collected between 29 October 1992 and 19 February 2013 123 
from the dolphins at the discretion of the attending veterinarian either as part of the routine 124 
preventative medicine program or as part of the clinical management of a natural E. 125 
rhusiopathiae infection. For venipuncture, the dolphins were trained to present their fluke to the 126 
attending veterinarian for sampling using 3- 4” 21 gauge Surflo winged infusion sets (Terumo 127 
Medical Corporation).  Blood was collected into BD Vacutainers (Becton Dickinson) containing 128 
activated thrombin for analysis in the on-site diagnostic laboratories.  The thrombin-coagulated 129 
blood was centrifuged at 1,500 rpm for 10 min, and the serum was decanted and frozen at -80 °C 130 
for further testing. 131 
Seroconversion following primovaccination 132 
An initial blood sample was collected from a subsample of ten dolphins immediately before the 133 
first immunization with the vaccine (ER BAC PLUS®).  The first booster immunizations were 134 
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administered 21 days later.  Post-vaccination blood samples were collected 14 (± 1) days 135 
following the first booster from all ten dolphins.   136 
IgG response after natural infection 137 
Natural E. rhusiopathiae infections were confirmed between 15 March 1993 and 30 September 138 
2002 in three dolphins by culturing E. rhusiopathiae from a blood sample (n = 2) or by 139 
observation of the pathognomonic diamond skin lesions with concurrent highly inflammatory 140 
blood profile (n = 1).  For blood culture, 1.5 ml whole blood was added to a 1.5 ml Wampole 141 
Isolator tube (Alere Inc)  pool-side after disinfecting the stopper with 10% Povidone-iodine.  142 
Upon arrival in the lab, the isolator tube was vortexed for at least 10 sec, and 0.3 ml of the 143 
content was withdrawn and inoculated onto a chocolate agar plate.  The agar plates were 144 
incubated at 37°C until colonies appeared.  Bacterial colonies were subsequently selected and 145 
identified using a ViTek automated bacterial identification system (BioMerieux Inc).  From each 146 
dolphin, serum samples collected prior to the infection (n = 3), on the day of bacteremia or the 147 
first day clinical signs were observed (n = 3), and at varying intervals in the convalescent period 148 
(n = 7). 149 
Biological variables influencing anti-Erysipelothrix titers 150 
A single serum sample was collected from each of 49 immunized dolphins after an average of 151 
five immunizations (median = 6, min = 2, max = 11).  In addition, a single serum sample was 152 
included from each of the three dolphins that were never immunized.  For each dolphin, the 153 
gender (female = 0, male = 1), age (days), number of immunizations, mean vaccination interval 154 
(defined as the sum of the number of days between subsequent immunization divided by the 155 
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number of immunizations received), history of natural infection (no = 0, yes = 1), history of 156 
adverse vaccine reaction (no = 0, yes = 1) and time (days) since last immunization was recorded.   157 
Serology 158 
A Fluorescent microbead-based immunoassay (FMIA) developed for pigs was modified for 159 
use in dolphins as described in Melero et al (2016). The immunogenic recombinant fragment of 160 
415 amino acids corresponded to the N-terminal half domain of SpaA protein called rSpaA415 161 
was used as antigen for the FMIA (Giménez-Lirola et al. 2012a).  Conjugation of the antigen to 162 
the magnetic beads was performed as previously described (Giménez-Lirola et al. 2012b).  The 163 
assay was performed at room temperature using flat bottom FMIA plates (Bio-Plex Pro™ Bio-164 
Rad). Coupled beads were mixed under constant vortexing at 500 rpm and diluted in storage 165 
buffer (0.1 M PBS, 10% goat serum (Gibco®, Life Technologies), 0.05% Tween 20, pH 7.2) to a 166 
final concentration of 2,500 beads/well (50 beads/µl). All serum samples were diluted 1:50 in 167 
assay buffer (0.1 M PBS, 10% goat serum (Gibco®, Life Technologies), 0.05% Tween 20, pH 168 
7.2). Then, 50 µl of the bead suspension and 50 µl of the diluted sample were added to each well. 169 
Plates were incubated on a shaker for 60 min at 500 rpm and washed three times with PBS 170 
containing 0.05% Tween 20 (PBST). Next, 50 µl of a 1:300 dilution of biotin-conjugated anti-171 
bottlenose dolphin IgG (Nollens et al. 2007) in assay buffer was added to each well and the plate 172 
was incubated on a shaker for 30 min. After three washing steps, 50 µl of a 1:100 dilution of 173 
streptavidin R-phycoerythrin conjugate (Moss) in assay buffer was added to each well. Finally, 174 
after 30 min of incubation on a shaker and three additional washing steps, the beads were 175 
resuspended in 100 µl of assay buffer and were analyzed using a flow cytometer (Luminex-200, 176 
Luminex Corp) at default settings set by the manufacturer for routine applications. Events were 177 
gated to exclude doublets and other aggregates. Median fluorescence intensity of the reporter 178 
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signal estimated from at least 50 beads was used for the data analysis. A well incubated with 179 
serum diluent served as a control for nonspecific serum reactivity. The Median fluorescence 180 
intensity data was corrected for background levels by subtracting the negative antigen signal from the 181 
positive antigen signal. All the samples were analyzed in duplicate in two separate independent 182 
runs by using the plate reader software (Bio-Plex ManagerTM version 6.0, Bio-Rad). 183 
Inconclusive samples were re-tested.  Results were reported as a ratio of the Median fluorescence 184 
intensity of each sample to the Median fluorescence intensity of a randomly selected reference 185 
sample. 186 
Statistical analysis 187 
Data for the analysis were obtained from 49 immunized bottlenose dolphins, and three negative 188 
control dolphins without history of disease or vaccination.  For the combined data set, a 189 
correlation between each independent variable (gender, age, number of immunizations, history of 190 
natural infection, history of adverse reaction, days since last immunization and mean number of 191 
days between immunizations) on the antibody index was determined using a linear regression to 192 
look for significance and predictability (r2).  Any variable that had a significance of p < 0.1 and 193 
r2 > 0.05 was considered for inclusion into a regression model. The independent variables 194 
matching the criteria for inclusion were then analyzed using a multiple linear regression to 195 
determine the significance of each variable’s contribution. Final variable inclusion or exclusion 196 
within the model was determined by a backward stepwise regression using the likelihood-ratio 197 
test between models with and without variables in question.  Assumptions (normality and 198 
homoscedasticity of residuals) of the regression model were visually assessed with quantile 199 
normal plots of residuals and the Cook-Weisberg test.  To determine the predicted probabilities 200 
for an animal having an adverse reaction as the number of vaccines increased were determined 201 
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by logistic regression of dependent variable adverse reactions (0 = no, 1 = yes) by the number of 202 
vaccines. If the model was significant (p < 0.1), then the predicted probabilities of experiencing a 203 
reaction were determined by using the “margins” command (Stata, 14, StataCorp). All statistical 204 
analysis were performed with a commercial software (Stata, 14, StataCorp) and values of p < 205 
0.05 were considered significant.  206 
RESULTS 207 
Seroconversion following primovaccination 208 
An increase in antibody levels to the bacterin (ER BAC PLUS®) was detected in all ten 209 
dolphins (Fig. 1).  The mean antibody index of the initial blood samples of the ten dolphins was 210 
0.5 (± 0.8).  The mean antibody index of post-vaccination blood samples was 17.3 (± 3.1).  On 211 
average a 311-fold rise in antibody index (SD = 301, median = 313, min = 7, max = 859) was 212 
detected.  The mean antibody index of the three unvaccinated negative control dolphins was 0.05 213 
(± 0.05).   214 
Seroconversion following natural infection 215 
An antibody response following natural E. rhusiopathiae infection was detected in all three 216 
dolphins (Fig. 2).  The mean antibody index of the initial blood samples of the three dolphins 217 
was 0.09 (± 0.08) and the mean antibody index of blood samples collected at the time of 218 
bacteremia (n = 2) or when skin lesions were first noted (n = 1) was 0.02 (± 0.03).  A peak 219 
antibody index level of 20.91 was detected in one of these dolphins 45 days post bacteremia.  By 220 
day 167 following bacteremia the antibody index of this dolphin had decreased to 1.76.  The 221 
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highest measured antibody index in the other two dolphins were 3.38 (day 62) and 1.17 (day 75), 222 
however, no prior collected sample was available from either animal. 223 
Adverse reactions 224 
Adverse reactions were identified in five dolphins following administration of vaccination four 225 
(n = 1), seven (n = 1), eight (n = 2) and 11 (n = 1).  The adverse reactions consisted of transient 226 
lethargy in all five dolphins with additional nausea in three dolphins without deleterious effects 227 
beyond the first hour following immunization.  Animals in which an adverse reaction was 228 
recognized were not immunized in subsequent years. 229 
Biological variables influencing anti-Erysipelothrix titers 230 
The surveyed population consisted of 22 male and 30 female bottlenose dolphins with a mean 231 
age of 4,786 (± 3,844) and 6,253 (± 3,073) days respectively.  The immunized dolphins (n = 49) 232 
had received on average five immunizations (median = 6, min = 2, max = 11).  Of the vaccinated 233 
dolphins, three dolphins had previously survived a natural infection, and an adverse vaccine 234 
reaction had been identified in five dolphins.  The shortest vaccination interval of 35 days was 235 
implemented in a one-year-old young dolphin that had only received the primer and one booster.  236 
The mean vaccination interval for the other dolphins (n = 48) ranged between 123 and 759 days 237 
(mean = 341 ± 157 days).  The dolphins had not been immunized between 23 and 2,920 days 238 
(mean = 464 ± 570 days, median = 353 days) at the time of sampling. 239 
Only adverse reaction (AR: F1,48 = 3.26, p = 0.08, r2 = 0.05) and number of vaccinations 240 
(Vaccine number, VN: F1,48 = 32.01, p < 0.001, r2 = 0.41) were considered for inclusion in a 241 
regression model (Table 1).  A regression model that included VN and AR (AR contribution: t = 242 
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1.06, p = 0.29; Model r2 = 0.43) or VN, AR and AR*VN (t = -0.85, p = 0.4) was not improved 243 
over a regression model with just VN (  = 0.94, p = 0.33, Table 1).  Therefore, only VN was 244 
used to predict index as follows: Index = 5.58 + 1.446*VN (Table 1).  However, the model did 245 
not appear to adequately describe the initial (< 3 vaccines) and late (greater than 7 vaccines) X,Y 246 
relationship or slope. Therefore, a negative exponential regression equation was evaluated and 247 
determined to produce the best fit (r2 = 0.47, p < 0.0001) for the data (Table 1, Fig. 3).   248 
Further, the logistic regression of AR verses VN exhibited an approximately significant 249 
positive correlation (Log(p/1-p) = -4.6515 + 0.3940*VN, p = 0.07, r2 = 0.1), and based on this 250 
relationship, the predicted probabilities for an adverse reaction at the median number of vaccines 251 
administered of six was 9.2 ± 4.6%.   At eleven vaccines, the maximum number administered, 252 
the probability of an AR occurring increased to 42.1 ± 27.0% (Fig. 4).  253 
 254 
DISCUSSION 255 
The results presented here suggest that the ER BAC PLUS® vaccine is effective in conferring 256 
protection against natural E. rhusiopathiae infections in bottlenose dolphins. Firstly, the vaccine 257 
was shown to be immunogenic to bottlenose dolphins, confirming earlier results (Nollens et al. 258 
2007, Bernal-Guadarrama et al. 2014).  Secondly, the ability to detect antibodies generated 259 
following both natural and vaccine-induced immunizations using a for bottlenose dolphins 260 
modified FMIA based on the major surface protein A indicated the presence of shared epitopes 261 
in this region between the ER BAC PLUS® 65 kDa protein antigen and the E. rhusiopathiae 262 
strains to which bottlenose dolphins are exposed.  This cross-reactivity is key to cross-protection.  263 
Thirdly, the antibody indices of the vaccinated bottlenose dolphins were within the same order of 264 
magnitude of the peak levels measured following natural infection. Until the agglutinating or 265 
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complement fixating activity of both natural and artificial induced antibodies have been 266 
determined, comparable antibody indices can be presumed to confer comparable degrees of 267 
protection.  Finally, where E. rhusiopathiae infections have historically occurred in the 268 
bottlenose dolphin populations housed at the two study sites in regular intervals (Sitt et al, 2010), 269 
erysipelas has not been diagnosed either ante-mortem or post-mortem in vaccinated bottlenose 270 
dolphins in the 10 years since the start of the vaccination program (unpublished data).  A 271 
challenge study during which vaccinated and unvaccinated bottlenose dolphins are exposed to E. 272 
rhusiopathiae would be required to unequivocally confirm that the vaccine confers protection 273 
against E. rhusiopathiae and to determine which antibody index level is protective.  However, 274 
such a study is impossible using bottlenose dolphins as subjects. 275 
Vaccine-induced induced antibodies were much longer-lived than antibodies generated 276 
following a natural E. rhusiopathiae infection.  Even though some bottlenose dolphins had not 277 
been vaccinated for a prolonged period of time (464 ± 570 days), the number of days since the 278 
last vaccination did not influence the animals’ antibody index.  Antibodies generated following a 279 
natural infection were shorter-lived and consequently having survived a natural E. rhusiopathiae 280 
infection did not influence the animals’ antibody index.  This difference in antibody half-life 281 
could be attributed to either the highly effective adjuvants admixed in the ER BAC PLUS® 282 
bacterin or due to the repeated exposure to the vaccine antigen. 283 
Because of the longevity of the vaccine- induced antibodies, the number of vaccinations had 284 
the highest impact on antibody levels. However, this relationship between number of 285 
vaccinations received and antibody level is not linear, and the protective benefit gained from 286 
each additional vaccination appears to taper between 5 and 7 vaccinations.   No other factors, 287 
including age, gender and ultimately also history of adverse reaction, significantly altered the 288 
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antibody levels in the studied bottlenose dolphin population.  In addition, an obvious benefit of a 289 
shorter vaccination interval on antibody levels was not identified. In contrast, an earlier study 290 
investigating the cellular immune response following vaccination with the bacterin indicated 291 
superior numbers of T-cells in bottlenose dolphins receiving six-monthly compared to annual 292 
booster vaccinations (Sitt et al. 2010).  The authors did however acknowledge that this superior 293 
T-cell memory did not translate in an improved anamnestic response and recommended the 294 
longer 12-month vaccination interval (Sitt et al. 2010). 295 
Our results support the hypothesis that the commercial porcine ER BAC PLUS® vaccine is 296 
effective in generating long-lived antibodies against E. rhusiopathiae in bottlenose dolphins and 297 
is therefore likely to confer protection against erysipelas. Considering the longevity of vaccine-298 
induced antibodies and the lower benefit but increasing risk of adverse reactions with each 299 
additional immunization, the vaccination interval could likely be prolonged beyond one year 300 
once multiple vaccinations have been received.  More research is needed to define the longevity 301 
of antibodies after repeated vaccination and in order to determine the optimal vaccination 302 
interval.  303 
 304 
 305 
 306 
 307 
 308 
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Table 1.  Regression model development for prediction of anti-Erysipelothrix antibody titers (Index) in response to 
vaccinations and the potential influence of biologic variables.   
 
Independent Variables 
Regression Parameters  
(F1,48, p value, r2) 
Age of Animal (Age d) 0.18, 0.67, 0.004 
Sex (Female = 0, Male = 1) 0.01, 0.93, 0.000 
Erysipelothrix Bacteremia (No =0, Yes = 1) 0.20, 0.66, 0.004 
Adverse Reaction (AR; No = 0, Yes = 1) 3.26, 0.08, 0.045 
Number of Vaccines (VN) 32.01, <0.01, 0.41 
Days since last vaccine (d) 0.01, 0.94, 0.000 
  
Multiple regression analysis  
Index = 5.716 + (1.381*VN) + (2.13* AR) + (-1.067*VN*AR) 9.71, <0.001, 0.35 
Independent Variables  
VN t = 4.92, p = <0.001 
AR t = 1.06, p = 0.296 
Interactions: AR by VN t = -0.85, p = 0.4 
Final Linear Model  
Index = 5.58 + 1.446*VN 27.8, <0.001, 0.37 
Negative Exponential Model  
Index = 18.6819 * [1 – exp(-0.2795*vaccines)] 40.92, <0.0001, 0.47 
 396 
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 399 
Fig. 1. The mean antibody index (± SD) of the initial (0.5 ± 0.8, n = 10) and post-vaccination 400 
samples (17.3 ± 3.1, n = 10) collected 14 (± 1) days following the booster immunization from 10 401 
bottlenose dolphins.  On average a 311-fold rise in antibody index (SD = 301, median = 313, min 402 
= 7, max = 859) was detected. 403 
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 404 
Fig. 2. The mean antibody index of samples collected from naturally infected bottlenose dolphins 405 
(n = 3) prior to infection (“initial”), at the time of acute infection (“infection”) and in the 406 
convalescent period (“convalescence”).  The highest antibody index level of 20.91 was detected 407 
in Dolphin #1 at 45 days post infection. 408 
409 
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 411 
Fig. 3. A negative exponential regression of antibody index verse vaccination number (r2 = 0.47, 412 
p = 0.001).  The negative exponential regression defines an exponential rise to a maximum, 413 
which visually occurs from 5 to 7 vaccinations.  Thus, the effectiveness of the vaccines at 414 
creating an antibody response appears to be leveling off with additional vaccines being of 415 
questionable value.   416 
417 
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Fig. 4. The logistic regression of adverse reaction versus number of vaccination (VN) was 419 
approaching significance (Log(p/1-p) = -4.6515 + 0.3940*VN, p = 0.07, r2 = 0.1). Based on this 420 
relationship, an increased probability of adverse reaction with increasing number of 421 
immunizations received was detected. 422 
